Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.61
$0.06(2.53%)
At close: 4:00 PM EDT
$2.61
$0.06(2.53%)
Day’s Range― - ―
52-Week Range$1.52 - $3.19
Previous CloseN/A
Volume129.84K
Average Volume (3M)721.60K
Market Cap
$208.68M
Enterprise Value$160.20
Total Cash (Recent Filing)$27.42M
Total Debt (Recent Filing)$9.21M
Price to Earnings (P/E)10.9
Beta0.73
Next Earnings
Nov 16, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding80,571,640
10 Day Avg. Volume654,871
30 Day Avg. Volume721,603
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)$78.30M
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe shift to strong profitability and margins improves internal funding capacity and reduces reliance on external capital. However, durability depends on recurring product sales because recent results also benefited from a milestone and an R&D law credit.
Debt-Free LiquidityA cash-rich, debt-free balance sheet gives Protalix flexibility to fund manufacturing, clinical development and regulatory work without near-term financing pressure. This strengthens resilience while the company advances its pipeline and commercial programs.
Elfabrio Commercial ExpansionAdditional geographic access and less frequent dosing can broaden Elfabrio adoption and improve its competitive positioning in Fabry disease. Partner-led commercialization also allows Protalix to participate in growth without building a large direct sales infrastructure.
Bears Say
Partner ConcentrationDependence on Chiesi and uneven ordering can make revenue timing difficult to forecast, even when underlying demand is healthy. This concentration also gives partner decisions greater influence over manufacturing volumes, cash conversion and reported results.
Non-Recurring Milestone DependenceThe milestone materially inflated first-half revenue and makes year-over-year performance less representative of recurring commercial economics. Future results will need sustained Elfabrio sales and supply revenue to maintain the improved earnings profile.
PRX-115 Clinical UncertaintyImmunogenicity and infusion-related reaction concerns may constrain dose selection, complicate development and delay advancement of PRX-115. Uncertainty over the final regimen could affect clinical timelines, development costs and the program’s eventual market positioning.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.52 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $208.68M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 72 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on Aug 12, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.06.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.02.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 7.819%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
PLX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong operational and financial positives — double-digit quarterly revenue growth, a >100% year-to-date revenue increase, meaningful Q2 net income, strong Elfabrio commercial momentum with regulatory and patent tailwinds, a solid cash position and advancing pipeline (PRX-115 with topline expected H2 2027). Offsetting risks include quarter-to-quarter revenue lumpiness and partner concentration (Chiesi), a reliance on a one-time $25M milestone in H1, increased cost of revenues and taxes, and clinical uncertainties around immunogenicity and regimen selection for PRX-115. Overall, the positives — particularly the robust revenue growth, improved profitability and cash position — outweigh the noted risks, though sustainability and immunogenicity remain items to monitor.View all PLX earnings summariesTechnical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.87% Insiders
2.82% Mutual Funds
1.04% Other Institutional Investors
86.99% Public Companies and
Individual Investors